Intuitive Surgical Director Amy Ladd sold 72 shares of the company's stock on August 11th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $393.10 per share, totaling approximately $28,303, leaving her with 179 shares valued at roughly $70,365. This sale represents a 28.69% decrease in her personal ownership stake.
The medical technology company recently reported strong quarterly financial results released on July 16th. Intuitive Surgical achieved revenue of $2.89 billion, surpassing analyst expectations of $2.83 billion, and posted earnings per share of $2.80 against a consensus estimate of $2.48. Revenue grew by 18.4% year-over-year, while the company maintained a net margin of 28.45% and a return on equity of 16.91%.
Institutional investor activity shows mixed signals alongside recent analyst adjustments. Several hedge funds, including Brighton Jones LLC and Main Street Financial Solutions LLC, significantly increased their stakes in the second quarter. However, major analysts like Stifel Nicolaus and BTIG Research lowered their price targets to $550 and $469 respectively, though the consensus rating remains a 'Moderate Buy' with a target price of $509.02.
💰 Q2 revenue hit $2.89B, beating estimates by $60M.
📈 EPS reached $2.80, topping the consensus of $2.48.
🏦 Institutional ownership stands at 83.64% with increased holdings.
📉 Stifel lowered price target to $550 while keeping 'buy'.
🔭 Full-year EPS forecast is $8.87 for current fiscal year.
📉 Director Amy Ladd sold 72 shares for $28,303 under a pre-arranged Rule 10b5-1 trading plan on August 11th.
💰 The company reported Q2 revenue of $2.89 billion, beating estimates by $60 million and growing 18.4% year-over-year.
📈 Intuitive Surgical posted earnings per share of $2.80, significantly topping the consensus estimate of $2.48.
🏦 Institutional ownership remains high at 83.64%, with Brighton Jones LLC increasing holdings by 24.9% in Q4.
📉 Analyst Stifel Nicolaus lowered its price target from $670 to $550 while maintaining a 'buy' rating.
📉 BTIG Research reduced its price objective from $512 to $469, citing a 'buy' recommendation.
📊 The stock trades at a P/E ratio of 45.96 with a market capitalization of $141.75 billion.
🔭 Analysts forecast full-year earnings per share of $8.87 for the current fiscal year.
🏥 Intuitive Surgical's core business focuses on da Vinci robotic-assisted surgical systems and related instruments.
📈 Royal Bank Of Canada reduced its price target to $600 but maintained an 'outperform' rating.
Bullish Signals
- Revenue $2.89B beat expectations of $2.83B.
- Earnings per share $2.80 beat consensus $2.48.
- Year-over-year revenue growth reached 18.4%.
- Net margin of 28.45% and ROE of 16.91%.
- Institutional investors increased stakes significantly.
Risk Factors
- Director Amy Ladd sold holdings (28.69% decrease).
- Stifel lowered price target from $670 to $550.
- BTIG reduced objective from $512 to $469.
- Royal Bank of Canada cut target from $650 to $600.
Bullish Signals
- Revenue of $2.89 billion exceeded analyst expectations of $2.83 billion, demonstrating strong market demand.
- Earnings per share of $2.80 beat the consensus estimate of $2.48 by $0.32, indicating operational efficiency.
- Year-over-year revenue growth of 18.4% highlights sustained business expansion in the medical robotics sector.
- Net margin of 28.45% and return on equity of 16.91% reflect robust profitability and capital allocation.
- Multiple institutional investors, including Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes significantly in recent quarters.
Risk Factors
- Director Amy Ladd sold a substantial portion of her holdings (28.69% decrease), which can sometimes signal reduced confidence or liquidity needs.
- Analyst Stifel Nicolaus lowered its price target from $670 to $550, suggesting potential valuation concerns despite the buy rating.
- BTIG Research reduced its price objective from $512 to $469, indicating a more conservative near-term outlook.
- Royal Bank Of Canada cut its price target from $650 to $600, reflecting some caution among major financial institutions.
Intuitive Surgical (ISRG) saw significant institutional activity in recent quarters, highlighted by BSN Capital Partners reducing its stake by 41.5% to 100,000 shares worth $49.6 million. Conversely, major funds like Norges Bank, J. Stern & Co., and Northwestern Mutual Wealth Management aggressively increased their holdings, with J. Stern raising its position by over 18,500% to own more than $1.2 billion in stock.
Analyst sentiment remains mixed regarding the company's valuation. While Barclays maintains an overweight rating with a $651 price target, Deutsche Bank and HSBC have downgraded their ratings or lowered targets to the low $300s. The consensus among twenty analysts is currently a Moderate Buy with an average price target of $509.02.
Insider trading data shows recent sales by executives Iman Jeddi and Gary Loeb, who sold shares under pre-arranged Rule 10b5-1 plans. Over the last ninety days, insiders have collectively sold approximately $2.8 million in stock, though they still retain a small 0.60% ownership stake in the company.
📉 BSN Capital reduced ISRG holdings by 41.5% to 100k shares.
🚀 J. Stern & Co. surged stake 18,504.6% to $1.2 billion value.
📈 Norges Bank added massive $2.86 billion position in Q4.
📉 Deutsche Bank downgraded stock with new $366 price target.
💼 Insiders sold 6,634 shares worth $2.8 million recently.
📉 BSN Capital Partners reduced its ISRG position by 41.5%, selling 71,000 shares to hold 100,000 shares valued at $49.6 million.
📈 Norges Bank established a new massive position worth $2.86 billion in the fourth quarter.
🚀 J. Stern & Co. LLP increased its stake by 18,504.6% to own 2.13 million shares valued at $1.2 billion.
📈 Northwestern Mutual Wealth Management raised its holdings by 1,043.3% to acquire an additional 1.22 million shares.
📈 Arrowstreet Capital Limited Partnership increased its position by 95.3% in the first quarter.
📉 Deutsche Bank lowered its price target from $440 to $366 and issued a sell rating.
📉 HSBC downgraded Intuitive Surgical from a buy to a hold with a $391 price objective.
📈 Barclays maintains an overweight rating with a high $651 price target.
📊 The stock currently trades at a PE ratio of 40.47 with a market cap of $124.82 billion.
💼 Insiders sold a total of 6,634 shares valued at $2.8 million over the last ninety days.
Bullish Signals
- Norges Bank and J. Stern & Co. increased stakes significantly.
- Northwestern Mutual added 1.2M shares, up over 1,000%.
Risk Factors
- Deutsche Bank and HSBC downgraded ratings or lowered price targets.
- Insiders sold $2.8 million in stock over last 90 days.
Bullish Signals
- Major institutional investors like Norges Bank and J. Stern & Co. have significantly increased their stakes, indicating strong confidence in the company's long-term prospects.
- Northwestern Mutual Wealth Management added over 1.2 million shares to its portfolio, representing a massive increase of more than 1,000%.
Risk Factors
- Deutsche Bank and HSBC have downgraded their ratings or lowered price targets, signaling potential concerns about the current valuation or growth trajectory.
- Insiders sold $2.8 million worth of stock in the last ninety days, which can sometimes indicate a lack of immediate confidence at the executive level.
HSBC downgraded Intuitive Surgical (NASDAQ:ISRG) from a Buy to a Hold rating, setting a $391 target price. This move follows a series of recent analyst adjustments, including Sanford Bernstein lowering its target to $685 and Jefferies reducing its objective to $515, though the consensus remains a Moderate Buy with an average target of $509.02.
The company reported strong quarterly financial results on July 16th, beating earnings estimates with $2.80 EPS versus a consensus of $2.48 and revenue of $2.89 billion against expectations of $2.83 billion. Revenue grew 18.4% year-over-year to $2.89 billion, while the business maintained a net margin of 28.45% and a return on equity of 16.91%, demonstrating robust profitability.
Despite positive earnings, insider selling activity was notable in June, with EVP Gary Loeb and SVP Iman Jeddi executing pre-arranged Rule 10b5-1 sales totaling over $2.5 million. Conversely, institutional investors showed significant accumulation in the fourth quarter, with Norges Bank, J. Stern & Co., and Northwestern Mutual increasing their stakes substantially.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which are deployed in hospitals globally for minimally invasive procedures. The company's business model relies on selling systems, instruments, and proprietary software while providing essential training and servicing support to maintain high margins and recurring revenue streams.
📉 HSBC downgraded stock to Hold with $391 target.
📈 Q2 EPS beat estimates at $2.80 vs $2.48 consensus.
💰 Revenue surged 18.4% YoY to reach $2.89 billion.
🛡️ Net margin remains strong at 28.45%.
🏦 Major institutions increased holdings in Q4.
📉 HSBC downgraded Intuitive Surgical from Buy to Hold with a $391 target price following recent analyst skepticism.
📈 The company beat Q2 earnings estimates significantly, reporting $2.80 EPS compared to the consensus of $2.48.
💰 Revenue reached $2.89 billion for the quarter, representing an 18.4% year-over-year increase.
🛡️ Intuitive Surgical maintained a healthy net margin of 28.45% and a return on equity of 16.91%.
📉 Insider selling occurred in June as EVP Gary Loeb and SVP Iman Jeddi sold shares under pre-arranged trading plans.
🏦 Major institutional investors including Norges Bank and J. Stern & Co. significantly increased their holdings in Q4.
🔬 The firm is best known for its da Vinci surgical systems used for minimally invasive procedures globally.
📊 Analyst consensus remains Moderate Buy with an average price target of $509.02 despite recent downgrades.
Bullish Signals
- Revenue hit $2.89B, beating estimates of $2.83B.
- EPS reached $2.80, surpassing the $2.48 consensus.
- Revenue grew 18.4% year-over-year showing market expansion.
- Net margins stayed robust at 28.45%.
- Norges Bank bought a $2.86B stake in Q4.
Risk Factors
- HSBC downgraded stock to Hold with lowered $391 target.
- Analysts Bernstein and Jefferies reduced targets to $685 and $515.
- Insiders sold 6,634 shares worth $2.79 million last quarter.
Bullish Signals
- Intuitive Surgical reported quarterly revenue of $2.89 billion, surpassing analyst estimates of $2.83 billion by a notable margin.
- The company achieved an EPS of $2.80, beating the consensus estimate of $2.48 by $0.32, indicating strong operational execution.
- Revenue grew 18.4% year-over-year, demonstrating continued market expansion and demand for robotic surgical systems.
- Net margins remained robust at 28.45%, reflecting the company's high-margin business model and pricing power.
- Return on equity stood at 16.91%, highlighting efficient capital deployment and strong shareholder value generation.
- Significant institutional accumulation occurred in Q4, with Norges Bank purchasing a stake worth approximately $2.86 billion.
Risk Factors
- HSBC downgraded the stock from Buy to Hold, citing concerns that may be reflected in their lowered $391 target price.
- Multiple other analysts recently reduced price targets, including Sanford Bernstein dropping its target to $685 and Jefferies to $515.
- Corporate insiders sold a total of 6,634 shares worth $2.79 million in the last quarter, signaling potential lack of confidence at the executive level.
Intuitive Surgical (ISRG) EVP Mark Brosius sold 28 shares of the company's stock on July 29th for a total value of $10,085.88 at an average price of $360.21 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and resulted in a 2.07% decrease in his direct ownership position, leaving him with 1,322 shares valued at approximately $476,198.
The company recently reported strong quarterly financial results announced on July 16th, beating analyst expectations for both earnings per share and revenue. Intuitive Surgical posted EPS of $2.80 compared to a consensus of $2.48 and generated revenue of $2.89 billion against an estimate of $2.83 billion. Revenue grew by 18.4% year-over-year, while the company maintained a net margin of 28.45% and a return on equity of 16.91%.
Institutional investor activity shows mixed signals with several funds increasing their stakes in the fourth quarter, including North Star Investment Management Corp which raised its position by 8.5%. However, analyst sentiment has softened recently, with Goldman Sachs lowering its price target to $558 and BTIG Research reducing its target from $512 to $469 while maintaining a buy rating.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which are used in minimally invasive procedures at hospitals and surgical centers globally. The company's stock currently trades at a price-to-earnings ratio of 40.45 with an average analyst target price of $517.21 based on ratings from twenty-one analysts.
📉 EVP sold 28 shares for $10,085.88 on July 29th.
💰 Q3 EPS hit $2.80, beating estimates by $0.32.
📈 Revenue reached $2.89 billion, up 18.4% year-over-year.
🏦 Institutional ownership is 83.64%; North Star added 8.5%.
📉 Goldman Sachs lowered target to $558; BTIG cut to $469.
📉 EVP Mark Brosius sold 28 shares of ISRG stock for $10,085.88 under a pre-arranged Rule 10b5-1 trading plan on July 29th.
💰 The company reported Q3 EPS of $2.80, beating the consensus estimate of $2.48 by $0.32.
📈 Revenue reached $2.89 billion for the quarter, representing an 18.4% increase year-over-year.
🏦 Institutional ownership remains high at 83.64%, with North Star Investment Management increasing its stake by 8.5% in Q4.
📉 Goldman Sachs lowered its price target to $558, while BTIG Research reduced its target from $512 to $469.
📊 The stock trades at a P/E ratio of 40.45 with an average analyst target price of $517.21.
🔬 Intuitive Surgical is best known for its da Vinci surgical systems used in minimally invasive procedures.
Bullish Signals
- Beat EPS expectations with $2.80 vs $2.48 consensus.
- Revenue grew robustly 18.4% YoY to $2.89 billion.
- Strong profitability: 28.45% net margin and 16.91% ROE.
- Institutional investors added holdings, including North Star +8.5%.
Risk Factors
- Goldman Sachs and BTIG Research recently reduced price targets.
- Stock trades below 50-day ($353.10) and 200-day ($454.32) averages.
Bullish Signals
- Intuitive Surgical beat earnings expectations significantly, reporting $2.80 EPS versus the consensus of $2.48.
- Revenue growth was robust at 18.4% year-over-year, reaching $2.89 billion for the quarter.
- The company maintains strong profitability with a net margin of 28.45% and a return on equity of 16.91%.
- Several institutional investors increased their holdings in Q4, including North Star Investment Management Corp which added 8.5% to its position.
Risk Factors
- Analyst price targets have been reduced recently by Goldman Sachs and BTIG Research, indicating some caution on valuation levels.
- The stock is trading below its 50-day and 200-day moving averages at $353.10 versus $401.70 and $454.32 respectively.
Intuitive Surgical (ISRG) shares fell 37% to $355 following Q2 earnings, where the company beat revenue estimates with 19% growth and non-GAAP EPS of $2.80. Despite the financial beat, management cut full-year procedure growth guidance for the da Vinci system to a range of 13.5%-15.5%, down from 18% in 2025, causing an 11% single-day drop in stock price.
The decline is attributed to specific headwinds including U.S. procedure deceleration due to ACA premium dynamics and GLP-1 drug usage reducing bariatric cases, alongside tariff exposure from manufacturing in Mexico, Germany, and China. Management repurchased $379 million of stock in Q2 at an average price above the current market level, while maintaining a robust cash position of $8.6 billion.
Analyst sentiment remains mixed but constructive long-term. Bernstein maintains an Outperform rating with a target of $685, citing the da Vinci 5 upgrade cycle and recurring revenue durability. However, the consensus price target sits at $484, implying roughly 36% upside from current levels as investors weigh near-term volatility against the company's dominant market position and fortress balance sheet.
📉 ISRG shares fell 37% YTD after procedure growth guidance cut to 13.5%-15.5%.
💰 Q2 revenue hit $2.89B, beating estimates with non-GAAP EPS of $2.80.
🛡️ Management repurchased $379M in Q2 while holding $8.6B cash on hand.
📉 U.S. da Vinci growth slowed to 12% due to GLP-1 impacts and payer dynamics.
🌏 International procedures surged 21%, with Europe and Asia both growing 20%.
📉 ISRG shares dropped 37% year-to-date to $355 after management cut full-year procedure growth guidance to 13.5%-15.5%.
💰 Company beat Q2 estimates with $2.89B revenue (up 18.54%) and non-GAAP EPS of $2.80, topping the consensus.
🛡️ Management repurchased $379 million in Q2 at an average price of $439, above the current trading level.
💸 The company holds a strong balance sheet with $8.6 billion in cash on hand.
📉 U.S. da Vinci procedure growth slowed to 12% in Q2 from 14% in Q1 due to payer dynamics and GLP-1 impacts.
🌏 International procedures grew 21%, with Europe and Asia both posting 20% growth.
🔧 Non-GAAP gross margin expanded to 70.0%, aided by a $36 million tariff refund.
🤖 Da Vinci 5 placements reached 246 of 468 total, representing a 24% increase in U.S. placements.
📈 Recurring revenue now accounts for approximately 85% of the company's total revenue.
🎯 Bernstein analyst targets $685 (92% upside), while the average Wall Street target is $484 (36% upside).
⚠️ Tariff exposure across Mexico, Germany, and China manufacturing compressed valuation multiples.
📉 CEO Dave Rosa cited high-single-digit declines in bariatric cases from GLP-1 usage as a key factor.
Bullish Signals
- Revenue grew 19% YoY to $2.89 billion.
- Non-GAAP EPS of $2.80 beat consensus.
- $379 million stock repurchase executed in Q2.
- $8.6 billion cash reserves on balance sheet.
- International procedures surged 21% in Q2.
Risk Factors
- Guidance cut to 13.5%-15.5%, down from 18% in 2025.
- U.S. da Vinci growth slowed to 12% in Q2.
- Bariatric cases declined due to GLP-1 drug competition.
- Tariffs in Mexico, Germany, and China compress valuation.
- Stock fell 37% YTD despite underlying business growth.
Bullish Signals
- ISRG beat Q2 estimates for the fifth consecutive quarter with revenue growing 19% year-over-year to $2.89 billion.
- Non-GAAP EPS of $2.80 significantly topped the consensus estimate of $2.5037.
- Management executed a $379 million stock repurchase in Q2 at an average price of $439, well above the current share price.
- The company maintains a fortress balance sheet with $8.6 billion in cash reserves.
- International procedures grew 21% in Q2, demonstrating strong global demand outside the U.S.
- Non-GAAP gross margin expanded to 70.0%, supported by a $36 million tariff refund and operational efficiency.
- Da Vinci 5 placements surged 24% in the U.S., indicating successful adoption of the newer robotic platform.
- Recurring revenue now comprises roughly 85% of total revenue, providing high durability and predictability.
- Bernstein maintains an Outperform rating with a $685 price target, citing the da Vinci 5 upgrade cycle as a key driver.
Risk Factors
- Management cut full-year procedure growth guidance to 13.5%-15.5%, down from 18% in 2025.
- U.S. da Vinci procedure growth decelerated to 12% in Q2 from 14% in the prior quarter.
- Bariatric cases faced high-single-digit declines due to reduced demand from GLP-1 weight loss drug usage.
- Tariff exposure across manufacturing hubs in Mexico, Germany, and China compressed valuation multiples.
- The stock has fallen 37% year-to-date despite the underlying business continuing to grow.
- Analyst consensus price target of $484 implies a 36% gap from current levels, reflecting near-term uncertainty.
Intuitive Surgical (ISRG) shares rose 5.82% to $357.15 following the announcement of a new patient awareness collaboration with Deion Sanders, known as Coach Prime. The partnership leverages Sanders' personal experience undergoing robotic-assisted surgery for bladder cancer to educate patients about surgical options and encourage informed discussions with physicians.
The initiative focuses on providing educational resources through the da Vinci surgical platform to help patients understand treatment considerations before making decisions. Intuitive Surgical's Chief Medical Officer, Jaime Wong, emphasized that the campaign prioritizes education over direct treatment promotion to support meaningful conversations between patients and healthcare providers regarding complex medical choices.
Intuitive Surgical maintains its position as the global leader in robotic-assisted minimally invasive surgery, having facilitated more than 20 million procedures worldwide using its da Vinci systems. The company highlights that trained surgeons utilize these platforms to perform precise, less invasive operations which can lead to fewer complications and shorter recovery periods for patients.
Despite the stock price increase, the article does not cite specific financial metrics such as revenue growth, earnings beats, or new contract values associated with this partnership. The news is primarily driven by brand visibility and public relations efforts rather than reported changes in company economics or operational performance.
📈 ISRG stock rose 5.82% to $357.15 after new campaign announcement.
🤝 Deion Sanders promotes robotic surgery using his personal bladder cancer experience.
🩺 Educational resources via da Vinci platform aid patient decision-making.
🌍 Over 20 million robotic-assisted procedures completed globally with da Vinci system.
⚠️ No specific financial data links campaign to revenue or margin impacts.
📈 ISRG stock price increased 5.82% to close at $357.15 after announcing the new awareness campaign.
🤝 The partnership features Deion Sanders ('Coach Prime') to promote understanding of robotic-assisted surgery options.
🩺 The campaign utilizes Coach Prime's personal experience with da Vinci surgery for bladder cancer as a case study.
📚 Intuitive Surgical plans to distribute educational resources via its da Vinci platform to assist patient decision-making.
👨⚕️ Chief Medical Officer Jaime Wong stated the initiative aims to facilitate better discussions between patients and doctors.
🌍 The company reports over 20 million robotic-assisted procedures completed globally using the da Vinci system.
🔬 Robotic systems are noted for enabling more precise, less invasive procedures with potential recovery benefits.
⚠️ The article lacks specific financial data linking this PR campaign to revenue or margin impacts.
Bullish Signals
- Stock price gained 5.82% after partnership announcement.
- Over 20 million procedures completed worldwide.
- New initiative strengthens brand reputation.
- Deion Sanders partnership boosts public awareness.
Risk Factors
- No concrete financial metrics like revenue or earnings provided.
- Campaign focuses on patient education, not new products.
- Reliance on single endorsement limits long-term strategic impact.
Bullish Signals
- Stock price gained 5.82% immediately following the announcement of the high-profile partnership.
- Company reinforces its market leadership status by citing over 20 million completed procedures worldwide.
- New educational initiative may strengthen brand reputation and patient trust in robotic surgery options.
- Partnership with a high-visibility figure like Deion Sanders increases public awareness of the technology.
Risk Factors
- Article does not provide concrete financial metrics (revenue, earnings, or guidance) to substantiate the stock gain.
- Campaign focuses on patient education rather than new product launches or operational expansions.
- Reliance on a single high-profile endorsement may limit long-term strategic impact compared to organic growth drivers.
Alamar Capital Management LLC acquired a new stake in Intuitive Surgical, Inc. (ISRG) during the first quarter, purchasing 3,563 shares valued at approximately $1.64 million. This filing highlights continued institutional interest alongside other funds like Fiduciary Financial Group and North Star Investment Management, which increased their positions by 2.1% and 8.5% respectively in the fourth quarter. Overall, institutional ownership remains high at 83.64%, indicating strong confidence from major investors despite recent price fluctuations.
Analyst sentiment regarding ISRG is mixed but leans positive with a consensus 'Moderate Buy' rating and an average price target of $523.46. While TD Cowen, Citigroup, and Robert W. Baird have recently lowered their price objectives to between $500 and $520, Goldman Sachs maintains a higher target of $558. The stock currently trades around $340.69, significantly below its 50-day moving average of $410.47 and 200-day average of $462.47, suggesting potential volatility or undervaluation relative to recent performance metrics.
Insider trading activity shows a net reduction in ownership by key executives and directors during the last quarter. EVP Gary Loeb sold 400 shares worth approximately $169,656 under a pre-arranged Rule 10b5-1 plan, while Director Amy L. Ladd reduced her holdings by 67.66% in a similar transaction. Collectively, insiders sold over 7,169 shares valued at more than $3 million, bringing total insider ownership down to 0.60% of the outstanding stock.
📈 Alamar Capital bought 3,563 ISRG shares worth $1.64M in Q1.
📊 Institutional ownership is 83.64%, with North Star increasing stakes by 8%.
📉 Stock trades below 50-day ($410.47) and 200-day ($462.47) averages.
🎯 Analysts rate it 'Moderate Buy' with a $523.46 average price target.
👔 Insiders sold 7,169 shares worth over $3M, dropping ownership to 0.60%.
📈 Alamar Capital Management LLC acquired a new stake in Intuitive Surgical (ISRG) in Q1, purchasing 3,563 shares valued at approximately $1.64 million.
📊 Institutional ownership of ISRG stands at 83.64%, with several funds like North Star Investment Management increasing their stakes by over 8% in the fourth quarter.
📉 The stock opened at $340.69, trading well below its 50-day moving average of $410.47 and 200-day average of $462.47.
🎯 Analyst consensus is a 'Moderate Buy' with an average price target of $523.46, though recent targets from TD Cowen and Citigroup have been lowered to the $500-$520 range.
👔 EVP Gary Loeb sold 400 shares worth $169,656 in June, while Director Amy L. Ladd sold 500 shares worth $236,730 in April under pre-arranged trading plans.
📉 Total insider selling reached 7,169 shares valued at over $3 million in the last quarter, reducing insider ownership to just 0.60% of the company's stock.
Bullish Signals
- 83.64% institutional ownership with new Alamar Capital acquisitions.
Risk Factors
- Executives sold over $3M in shares last quarter.
- Analysts lowered price targets to $500-$520.
Bullish Signals
- Strong institutional backing with 83.64% of shares held by institutional investors, including significant new acquisitions from Alamar Capital Management LLC.
- Analyst consensus remains 'Moderate Buy' with an average price target of $523.46, suggesting potential upside from current levels around $340.
Risk Factors
- Recent insider selling activity is notable, with executives and directors collectively offloading over $3 million in shares during the last quarter.
- Several major analysts have recently lowered their price targets to between $500 and $520, indicating some near-term caution or valuation concerns.
Shares of Intuitive Surgical (NASDAQ:ISRG) hit a new 52-week low around $346 on Monday, driven by JPMorgan Chase lowering its price target from $550 to $450 while maintaining an overweight rating. The stock has faced mixed analyst sentiment recently, with Deutsche Bank cutting its target to $366 and assigning a 'sell' rating, though other firms like Stifel Nicolaus and Wall Street Zen have raised targets or upgraded ratings to 'buy'.
Despite the recent price decline, Intuitive Surgical reported strong quarterly financial results on July 16th. The company posted revenue of $2.89 billion, beating estimates by $57 million, with earnings per share (EPS) of $2.80 versus a consensus of $2.48. Revenue grew 18.4% year-over-year, and the firm maintained healthy margins at 28.45% and a return on equity of 17.09%.
Institutional ownership remains high at 83.64%, with several hedge funds increasing their stakes in the fourth quarter, including North Star Investment Management Corp which raised its position by 8.5%. The company's market capitalization stands at approximately $124 billion, trading below its 50-day and 200-day moving averages, reflecting current market caution despite solid operational performance.
📉 ISRG shares hit 52-week low of $346.10 after analyst downgrades.
💰 Q2 revenue surged 18.4% to $2.89 billion, beating expectations.
📈 EPS reached $2.80, surpassing consensus by $0.32.
🏦 Institutional ownership stands strong at 83.64%.
🔮 Full-year EPS projected at $8.61.
📉 ISRG shares hit a new 52-week low of $346.10 following JPMorgan's price target reduction from $550 to $450.
📊 Deutsche Bank downgraded the stock to 'sell' with a lowered price target of $366, contrasting with recent upgrades from Stifel and Wall Street Zen.
💰 The company reported Q2 revenue of $2.89 billion, an 18.4% year-over-year increase that beat analyst expectations.
📈 EPS reached $2.80 for the quarter, surpassing the consensus estimate of $2.48 by $0.32.
🏦 Institutional ownership is robust at 83.64%, with multiple hedge funds increasing their holdings in Q4.
📉 The stock trades below its 50-day moving average ($412.30) and 200-day moving average ($464.06).
💵 Net margins remain strong at 28.45% with a return on equity of 17.09%.
🔮 Analysts project full-year EPS of $8.61 for the current fiscal year.
🏥 Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems.
Bullish Signals
- Revenue grew 18.4% YoY to $2.89 billion.
- EPS of $2.80 beat estimates by $0.32.
- Net margins at 28.45% and ROE at 17.09%.
- Institutional ownership reached 83.64% with stake increases.
- Upgraded to 'buy' by Wall Street Zen.
Risk Factors
- JPMorgan lowered target to $450 as stock hit 52-week low.
- Deutsche Bank cut target to $366 with a sell rating.
- Stock trades below 50-day ($412.30) and 200-day ($464.06) averages.
- Mixed outlook with seven holds, one sell, and some buys.
Bullish Signals
- Revenue grew 18.4% year-over-year to $2.89 billion, significantly beating analyst expectations of $2.83 billion.
- The company reported EPS of $2.80, which exceeded the consensus estimate of $2.48 by $0.32.
- Net margins remained healthy at 28.45% and return on equity stood at 17.09%.
- Several institutional investors increased their stakes in Q4, including North Star Investment Management Corp raising its position by 8.5%.
- Wall Street Zen upgraded the stock from 'hold' to 'buy', and Stifel Nicolaus lowered its target while maintaining a 'buy' rating.
- The company maintains a dominant market position with high institutional ownership at 83.64%.
Risk Factors
- JPMorgan Chase lowered its price target from $550 to $450, contributing to the stock hitting a new 52-week low.
- Deutsche Bank cut its price target to $366 and assigned a 'sell' rating, indicating bearish sentiment among some analysts.
- The stock is currently trading below both its 50-day simple moving average ($412.30) and 200-day simple moving average ($464.06).
- Analyst consensus includes seven 'Hold' ratings and one 'Sell' rating alongside the Buy ratings, reflecting mixed outlooks.
Intuitive Surgical (NASDAQ:ISRG) faces a mixed analyst outlook following a cluster of price target reductions from major brokerages on Friday. Citigroup lowered its target from $590 to $500, while BTIG Research, Robert W. Baird, and Sanford C. Bernstein also cut their targets to $469, $500, and $685 respectively, though most maintained 'buy' or 'outperform' ratings. Conversely, HSBC recently decreased its target but kept a buy rating, highlighting a divergence in analyst sentiment regarding the stock's immediate valuation.
The company reported strong quarterly financial results on April 21st, beating consensus estimates with $2.50 EPS and $2.77 billion in revenue, representing a 23% year-over-year increase. The firm achieved a net margin of 28.45% and a return on equity of 17.09%, demonstrating robust profitability despite the recent analyst downgrades. Analysts anticipate an EPS of $8.62 for the current fiscal year, suggesting continued growth expectations persist among the investment community.
Insider trading activity shows mixed signals with executives Gary Loeb and Iman Jeddi selling shares under pre-arranged Rule 10b5-1 plans in June, totaling over $3 million in sales. However, institutional ownership remains high at 83.64%, with significant additions from Regent Peak Wealth Advisors, Hyperion Asset Management, and Northside Capital Management during the second quarter, indicating continued confidence from large capital holders despite recent insider offloading.
📉 Citigroup lowered price target to $500 while maintaining 'buy' rating.
📈 Q1 revenue hit $2.77B, beating estimates with 23% year-over-year growth.
💰 Executives sold shares totaling over $2.5 million under pre-arranged plans.
📊 Institutional investors own 83.64% of outstanding stock as hedge funds buy in.
🔮 Analysts forecast $8.62 EPS for the current fiscal year.
📉 Citigroup reduced its price target for Intuitive Surgical from $590.00 to $500.00 while maintaining a 'buy' rating.
📉 BTIG Research, Robert W. Baird, and Sanford C. Bernstein also lowered their respective price targets on Friday.
📈 The company reported Q1 EPS of $2.50, beating the consensus estimate of $2.08 by $0.42.
💰 Revenue reached $2.77 billion for the quarter, up 23% year-over-year against a consensus of $2.62 billion.
📊 Intuitive Surgical achieved a net margin of 28.45% and a return on equity of 17.09% in the latest quarter.
👔 EVP Gary Loeb sold 400 shares worth $169,656 under a Rule 10b5-1 trading plan on June 10th.
👔 SVP Iman Jeddi sold 5,625 shares worth $2.37 million under a pre-arranged plan on June 1st.
📈 Regent Peak Wealth Advisors increased its stake by 7.2% to own 800 shares valued at $318,000.
📈 Hyperion Asset Management lifted its position by 49.8%, now holding 419,329 shares worth $166.76 million.
📈 Northside Capital Management initiated a new stake valued at $669,000 during the second quarter.
🏦 Institutional investors and hedge funds own 83.64% of the company's outstanding stock.
🔮 Analysts anticipate Intuitive Surgical will post $8.62 EPS for the current fiscal year.
Bullish Signals
- Revenue beat estimates by $150 million at $2.77 billion.
- Net margin reached 28.45% with strong operational efficiency.
- Quarterly revenue grew 23% year-over-year.
- Institutional holdings increased nearly 50% in Q2.
- Analysts anticipate EPS of $8.62 for the fiscal year.
Risk Factors
- Citigroup cut target to $500 from $590 due to valuation concerns.
- Multiple analysts including BTIG, Baird, and Bernstein recently lowered targets.
- Executives Loeb and Jeddi sold over $3 million in June shares.
Bullish Signals
- Intuitive Surgical reported revenue of $2.77 billion, which beat the consensus estimate of $2.62 billion by $150 million.
- The company achieved a net margin of 28.45% and a return on equity of 17.09%, indicating strong operational efficiency.
- Quarterly revenue grew 23% year-over-year, demonstrating sustained demand for the da Vinci surgical systems.
- Major institutional investors like Hyperion Asset Management increased their holdings by nearly 50% in the second quarter.
- Analysts anticipate an EPS of $8.62 for the current fiscal year, reflecting continued growth expectations.
- Despite recent insider sales, a significant majority of shares (83.64%) are held by institutional investors and hedge funds.
Risk Factors
- Citigroup reduced its price target from $590 to $500, citing potential valuation concerns despite maintaining a buy rating.
- Multiple other analysts including BTIG Research, Robert W. Baird, and Sanford C. Bernstein recently lowered their price targets.
- Executives Gary Loeb and Iman Jeddi sold a combined total of over $3 million in shares during June under pre-arranged plans.
Intuitive Surgical (NASDAQ:ISRG) shares experienced a significant gap down, opening at $365.03 after closing the previous session at $402.33. This decline was primarily triggered by JPMorgan Chase lowering its price target from $550.00 to $450.00, despite maintaining an overweight rating on the stock. The immediate market reaction saw shares trade around $355.92 with elevated volume of 2.26 million shares.
The broader analyst sentiment surrounding ISRG has become increasingly mixed in recent weeks. While JPMorgan cut its target, Deutsche Bank reduced its price objective to $366.00 and assigned a sell rating. Conversely, HSBC lowered its target but maintained a buy rating, and Sanford Bernstein cut its target while keeping an outperform rating. The aggregate consensus remains a Moderate Buy with an average price target of $523.46.
Despite the recent analyst downgrades, Intuitive Surgical reported strong quarterly fundamentals in late April. The company posted earnings per share of $2.50, beating estimates of $2.08, and generated revenue of $2.77 billion, which exceeded expectations of $2.62 billion. Revenue grew 23% year-over-year, supported by a net margin of 28.45% and a return on equity of 17.09%.
Institutional ownership remains robust at 83.64%, with notable activity from hedge funds in the fourth quarter. Newbridge Financial Services Group Inc. increased its position by 300%, while Turning Point Benefit Group Inc. grew its stake by over 800%. The company maintains a market capitalization of $122.33 billion and trades at a P/E ratio of 39.57.
📉 Analysts cut price targets to $366–$450 amid bearish sentiment.
💰 Q1 revenue hit $2.77B, beating estimates by $150M.
📈 EPS reached $2.50, surpassing the $2.08 consensus estimate.
🚀 Revenue grew 23% YoY driven by robotic system demand.
🎯 Average analyst target is $523.46 with a Moderate Buy rating.
📉 JPMorgan Chase lowered its price target on Intuitive Surgical from $550.00 to $450.00, causing shares to gap down significantly.
📊 Deutsche Bank reduced its price target to $366.00 and issued a sell rating, adding to recent bearish analyst sentiment.
💰 Intuitive Surgical reported Q1 revenue of $2.77 billion, beating analyst estimates of $2.62 billion by $150 million.
📈 Earnings per share reached $2.50, surpassing the consensus estimate of $2.08 by a margin of $0.42.
🚀 Revenue grew 23% year-over-year, driven by strong demand for robotic-assisted surgical systems.
💵 The company achieved a net margin of 28.45% and a return on equity of 17.09% during the quarter.
🏦 Institutional ownership stands at 83.64%, indicating continued confidence from major investors.
📉 Hedge fund activity was mixed, with Newbridge Financial increasing its stake by 300% while others acquired new positions.
🎯 The average analyst price target remains $523.46, suggesting a Moderate Buy consensus despite recent cuts.
📉 Technical indicators show the stock trading below its 50-day moving average of $415.28 and 200-day average of $467.88.
Bullish Signals
- Revenue beat estimates at $2.77 billion.
- Earnings per share hit $2.50, beating consensus.
- Revenue grew 23% year-over-year.
- Net margin reached 28.45% with ROE of 17.09%.
- Institutional ownership stands at 83.64%.
Risk Factors
- JPMorgan cut target to $450.00 causing sharp gap down.
- Deutsche Bank lowered target to $366.00 with sell rating.
- Stock trades below 50-day ($415.28) and 200-day ($467.88) averages.
- Mizuho and Weiss Ratings issued neutral or hold ratings.
Bullish Signals
- Intuitive Surgical reported revenue of $2.77 billion, which beat analyst estimates of $2.62 billion.
- The company posted earnings per share of $2.50, significantly beating the consensus estimate of $2.08.
- Revenue grew 23% year-over-year, demonstrating strong top-line growth in its core business.
- The firm achieved a healthy net margin of 28.45% and a return on equity of 17.09%.
- Institutional ownership remains high at 83.64%, with several hedge funds increasing their stakes in Q4.
Risk Factors
- JPMorgan Chase lowered its price target from $550.00 to $450.00, triggering a sharp gap down in the stock.
- Deutsche Bank reduced its price target to $366.00 and assigned a sell rating to the company.
- The stock is currently trading below both its 50-day moving average ($415.28) and 200-day moving average ($467.88).
- Several other analysts, including Mizuho and Weiss Ratings, have issued neutral or hold ratings on the stock.
Intuitive Surgical (ISRG) reported robust second-quarter 2026 financial results, driven by significant growth in both its core da Vinci and newer Ion robotic surgery platforms. Total revenue reached $2.89 billion, representing a 19% year-over-year increase from the prior year's $2.44 billion. This expansion was fueled by a 15% rise in da Vinci procedure volume and a substantial 36% surge in Ion procedure volume, alongside higher leasing revenue for its surgical systems.
The company demonstrated strong operational performance with GAAP income from operations climbing to $972 million, up from $743 million in the previous year. Non-GAAP income from operations also saw a notable increase to $1.22 billion compared to $0.95 billion. Net income attributable to Intuitive Surgical rose to $818 million, or $2.29 per diluted share, reflecting improved profitability and cash generation capabilities despite higher share-based compensation expenses.
Intuitive concluded the quarter with a healthy balance sheet, holding $8.63 billion in cash, cash equivalents, and investments, an increase of $650 million driven by operational cash flow. CEO Dave Rosa highlighted the strength of the company's portfolio, emphasizing the successful integration of digital solutions alongside its established robotic systems to deliver better patient outcomes and broader access to minimally invasive care globally.
📈 Q2 2026 revenue surged 19% to $2.89 billion.
🔬 Instruments revenue grew 18% to $1.73 billion.
🤖 da Vinci placements rose to 468 units, including 246 da Vinci 5s.
💰 GAAP income expanded to $972 million; cash reached $8.63 billion.
🚀 Ion procedure volume jumped 36% year-over-year.
📈 Second quarter 2026 revenue surged to $2.89 billion, marking a 19% increase from the same period in 2025.
🔬 Instruments and accessories revenue grew by 18% to $1.73 billion, driven by higher procedure volumes across both da Vinci and Ion systems.
🤖 Systems revenue reached $685 million, reflecting increased placements of 468 da Vinci surgical systems compared to 395 in the prior year.
💰 GAAP income from operations expanded to $972 million, while non-GAAP income from operations rose to $1.22 billion.
📉 Net income attributable to Intuitive Surgical hit $818 million, translating to $2.29 per diluted share versus $1.81 in the previous year.
💵 The company ended the quarter with $8.63 billion in cash and investments, up $650 million from the start of the period.
🚀 Ion procedure volume experienced a significant 36% growth rate compared to the second quarter of 2025.
📊 da Vinci system placements included 246 units of the newer da Vinci 5 model, showing continued adoption of advanced technology.
🌍 CEO Dave Rosa emphasized the company's commitment to helping customers deliver better patient outcomes and lower costs globally.
Bullish Signals
- Revenue grew 19% year-over-year to $2.89 billion.
- Instruments revenue increased 18% to $1.73 billion.
- Ion procedure volume surged 36%.
- GAAP income from operations rose 31% to $972 million.
- Non-GAAP net income per share reached $2.80.
- Placed 468 da Vinci systems in the quarter.
- Cash and investments grew to $8.63 billion.
Bullish Signals
- Revenue grew 19% year-over-year to $2.89 billion, demonstrating strong market demand for minimally invasive care solutions.
- Instruments and accessories revenue increased by 18% to $1.73 billion, indicating robust recurring revenue streams from existing installed bases.
- Ion procedure volume surged 36%, signaling successful adoption of the company's newer endoluminal system technology.
- GAAP income from operations rose 31% to $972 million, reflecting improved operational efficiency and margin expansion.
- Non-GAAP net income per diluted share increased to $2.80 from $2.19 in the prior year, showing strong underlying profitability.
- The company placed 468 da Vinci systems in the quarter, including 254 under operating lease arrangements, expanding its recurring revenue model.
- Cash and investments grew by $650 million to reach $8.63 billion, providing ample liquidity for future growth initiatives or share repurchases.
Bank of New York Mellon Corp reduced its stake in Intuitive Surgical, Inc. (ISRG) by 9.4% during the first quarter, selling 369,852 shares. Following this transaction, BNY Mellon holds approximately 1.00% of the company's stock, valued at $1.637 billion. While major institutions trim positions, several smaller hedge funds and wealth management firms increased their holdings in the fourth quarter, though these new stakes are relatively minor in total value compared to the large institutional owner.
Analyst sentiment regarding ISRG remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a target price of $565.31. Recent analyst actions include Citigroup reissuing a 'buy' rating, Goldman Sachs setting a $558 price objective, and Piper Sandler reaffirming an 'overweight' rating with a $580 target. Conversely, Jefferies Financial Group cut its price objective to $515 and assigned a 'hold' rating, while Raymond James lowered its target to $577.
Intuitive Surgical reported strong financial performance in the quarter ended April 21st, posting earnings per share of $2.50 against a consensus estimate of $2.08. Revenue reached $2.77 billion, representing a 23% year-over-year increase compared to analyst expectations of $2.62 billion. The company achieved a net margin of 28.15% and a return on equity of 15.98%, with equities research analysts forecasting an EPS of 8.57 for the current fiscal year.
The medical technology company, headquartered in Sunnyvale, California, specializes in robotic-assisted surgical systems like the da Vinci platform. With a market capitalization of $137.76 billion and a P/E ratio of 47.15, ISRG trades above its 200-day simple moving average of $469.98 but below its 50-day average of $418.39. The stock has seen significant volatility over the past year, ranging from a low of $378.50 to a high of $603.88.
📉 BNY Mellon sold 369,852 shares, reducing stake by 9.4%.
💰 Revenue hit $2.77B, beating estimates by $150M.
📈 EPS reached $2.50, surpassing the $2.08 consensus.
🚀 Revenue grew 23% year-over-year on strong demand.
🎯 Consensus analyst target price is set at $565.31.
📉 Bank of New York Mellon Corp sold 369,852 shares of ISRG in Q1, reducing its position by 9.4% while retaining a stake worth $1.637 billion.
📈 Several smaller institutional investors increased their stakes in Q4, including Newbridge Financial Services Group which lifted holdings by 300%.
💰 Intuitive Surgical reported quarterly revenue of $2.77 billion, beating analyst estimates of $2.62 billion by $150 million.
📊 The company posted EPS of $2.50, surpassing the consensus estimate of $2.08 and achieving a net margin of 28.15%.
🚀 Revenue grew 23% year-over-year, demonstrating continued strong demand for robotic surgical systems.
📝 Citigroup reissued a 'buy' rating on ISRG, while Goldman Sachs set a price objective of $558.
⚠️ Jefferies Financial Group cut its price target to $515 and downgraded the stock to a 'hold' rating.
🎯 Piper Sandler reaffirmed an 'overweight' rating with a price target of $580 on ISRG shares.
📉 The consensus analyst target price for Intuitive Surgical is currently set at $565.31.
📈 The stock trades at a P/E ratio of 47.15 with a market capitalization of $137.76 billion.
🏥 ISRG specializes in da Vinci surgical systems that enable minimally invasive procedures for hospitals.
📉 The stock price has fluctuated between a twelve-month low of $378.50 and a high of $603.88.
Bullish Signals
- Beat EPS estimates at $2.50 vs $2.08 consensus.
- Revenue grew 23% YoY to $2.77 billion.
- Net margin stands at 28.15% with ROE of 15.98%.
- Citigroup reissued 'buy' rating on ISRG.
- Piper Sandler set price target at $565.31.
Risk Factors
- Jefferies cut target to $515 with 'hold' rating.
- Raymond Financial lowered target from $615 to $577.
- BNY Mellon reduced holdings by 9.4%.
- High P/E of 47.15 limits upside if growth slows.
Bullish Signals
- Intuitive Surgical beat quarterly earnings estimates significantly, reporting $2.50 EPS versus the consensus of $2.08.
- Revenue growth remains robust at 23% year-over-year, reaching $2.77 billion for the quarter.
- The company maintains healthy profitability with a net margin of 28.15% and a return on equity of 15.98%.
- Citigroup reissued a 'buy' rating on ISRG, reinforcing positive analyst sentiment.
- Piper Sandler reaffirmed an 'overweight' rating with a price target of $580.
- Analyst consensus remains 'Moderate Buy' with a collective target price of $565.31.
Risk Factors
- Jefferies Financial Group cut its price objective to $515 and assigned a 'hold' rating, indicating some caution.
- Raymond Financial reduced its price target from $615 to $577 despite maintaining an 'outperform' rating.
- BNY Mellon's significant reduction in holdings by 9.4% suggests institutional investors are trimming exposure.
- The stock trades at a high P/E ratio of 47.15, which may limit upside potential if growth slows.
Institutional ownership of Intuitive Surgical, Inc. (NASDAQ:ISRG) saw mixed activity in the first quarter, with AMF Tjanstepension AB reducing its stake by 19.4% to 171,089 shares valued at $78.87 million. Conversely, several other major funds increased their positions significantly, including Teachers Retirement System of Kentucky boosting holdings by 72.6% and LGT Fund Management Co Ltd increasing its stake by 565.6%. These shifts reflect varying institutional strategies regarding the medical robotics leader.
Analyst sentiment remains cautiously optimistic despite a recent downgrade from Zacks Research, which changed its rating to 'hold.' Other major firms like Barclays and BTIG maintain 'overweight' or 'buy' ratings with price targets ranging from $574 to $651. The consensus average price target sits at $569.20, while the stock trades near its 50-day moving average of $422.09.
Insider trading activity shows executives Gary Loeb and Iman Jeddi sold shares totaling over $3 million in the last 90 days under pre-arranged Rule 10b5-1 plans. These sales represent a decrease in their personal holdings but are disclosed as part of standard trading plans rather than immediate negative signals about company fundamentals.
📉 AMF Tjanstepension AB sold 41,307 shares, reducing position by 19.4%.
📈 Teachers Retirement System of Kentucky added 20,280 shares, up 72.6%.
🚀 LGT Fund Management Co Ltd increased holding by 565.6% in Q1.
📉 Zacks Research downgraded stock from 'strong-buy' to 'hold'.
💰 Barclays maintains 'overweight' rating with $651 price objective.
📉 AMF Tjanstepension AB lowered its ISRG position by 19.4% during Q1, selling 41,307 shares.
📈 Teachers Retirement System of Kentucky increased its stake by 72.6%, acquiring an additional 20,280 shares.
🚀 LGT Fund Management Co Ltd grew its ISRG holding by 565.6% in the first quarter.
📊 Zacks Research downgraded Intuitive Surgical from 'strong-buy' to 'hold' on March 30th.
💰 Barclays maintains an 'overweight' rating with a $651 price objective for ISRG.
👔 EVP Gary Loeb sold 400 shares worth $169,656 under a Rule 10b5-1 trading plan.
📉 SVP Iman Jeddi reduced his personal stake by 46.53% via a sale of 5,625 shares.
🏢 Institutional investors collectively own 83.64% of Intuitive Surgical's outstanding stock.
📈 The company has a market capitalization of $144.07 billion and a PEG ratio of 3.31.
🎯 MarketBeat consensus price target for ISRG is set at $569.20.
Bullish Signals
- Teachers Retirement and LGT increased stakes Q1.
- Barclays rates overweight with $651 price target.
Risk Factors
- Zacks downgraded Intuitive Surgical from strong-buy to hold.
- Truist cut price target from $650 to $580.
Bullish Signals
- Multiple institutional investors, including Teachers Retirement System and LGT Fund Management, significantly increased their stakes in the first quarter, indicating confidence in the company's long-term prospects.
- Major analysts like Barclays maintain an 'overweight' rating with a high price target of $651, suggesting strong future growth potential relative to current valuation.
Risk Factors
- Zacks Research recently downgraded Intuitive Surgical from a 'strong-buy' to a 'hold' rating, signaling some analysts see limited near-term upside.
- Truist Financial reduced its price objective from $650 to $580, reflecting a more conservative valuation outlook for the stock.
Intuitive Surgical (ISRG) is preparing to release its Q2 2026 earnings results after market close on Thursday, July 16th. Analysts project the company will report earnings per share of $2.48 and revenue of $2.8249 billion for the quarter. The upcoming earnings call is scheduled for 4:30 PM ET, with investors encouraged to review the latest summary page for details on the conference.
The medical technology firm previously reported strong financials in April, posting $2.50 EPS which significantly beat analyst consensus estimates of $2.08 by $0.42. Revenue reached $2.77 billion, surpassing expectations of $2.62 billion, while net margins stood at 28.15% and year-over-year revenue growth was a robust 23.0%. Analysts maintain forward guidance with average EPS expectations of $9 for the current fiscal year and $10 for the next.
Recent insider activity shows mixed signals as Director Amy Ladd sold 119 shares in April under a pre-arranged trading plan, while EVP Gary Loeb reduced his position by 6.54% in June. Despite these sales, institutional investors have been accumulating stakes, with Brighton Jones LLC increasing its holdings by 24.9% and Meeder Asset Management Inc. boosting its position by over 150% in the fourth quarter.
Intuitive Surgical continues to dominate the robotic-assisted surgery market with its da Vinci systems, which enable minimally invasive procedures for hospitals and surgical centers. The company generates revenue through the sale of surgical platforms, reusable and disposable instruments, proprietary software, and essential training and servicing support. With a market cap of $147 billion and a PE ratio of 50.32, the stock trades near its 50-day moving average.
📅 Q2 2026 earnings release scheduled for Thursday, July 16th.
💰 Last quarter beat estimates with $2.50 EPS and $2.77B revenue.
📈 Revenue grew 23.0% year-over-year showing strong top-line momentum.
🏆 Achieved 28.15% net margin and 15.98% return on equity.
🔬 Core business relies on da Vinci surgical systems for hospitals.
📅 Intuitive Surgical is set to release Q2 2026 earnings on Thursday, July 16th, with analysts expecting $2.48 EPS and $2.8249 billion in revenue.
💰 The company previously beat estimates in April with $2.50 EPS versus a consensus of $2.08 and revenue of $2.77 billion against expectations of $2.62 billion.
📈 Revenue grew 23.0% year-over-year in the last reported quarter, demonstrating strong top-line momentum for the medical device leader.
🏆 Intuitive Surgical achieved a net margin of 28.15% and a return on equity of 15.98% during its last earnings period.
📉 Director Amy Ladd sold 119 shares in April, while EVP Gary Loeb reduced his stake by 6.54% in June under Rule 10b5-1 plans.
🏛️ Institutional ownership remains high at 83.64%, with Brighton Jones LLC increasing its stake by 24.9% and Meeder Asset Management Inc. adding 153.2% to its position.
📊 The stock currently trades at a PE ratio of 50.32 with a market capitalization of $147.01 billion.
🔬 The company's core business revolves around the da Vinci surgical systems, which provide minimally invasive capabilities to hospitals and surgical centers.
💻 Revenue streams include sales of surgical platforms, instruments, accessories, proprietary software, as well as training and clinical support services.
Bullish Signals
- Beat estimates with $2.50 EPS vs $2.08 consensus.
- Revenue grew 23.0% year-over-year last quarter.
- Net margins remained healthy at 28.15%.
- Analysts project $9 and $10 EPS for next two years.
Risk Factors
- Director Amy Ladd sold 119 shares, reducing position by nearly 50%.
- EVP Gary Loeb sold 400 shares, decreasing ownership by 6.54%.
- Insiders collectively sold over $3 million in 7,169 shares last three months.
Bullish Signals
- The company recently beat analyst estimates significantly with $2.50 EPS compared to a consensus of $2.08, indicating strong operational execution.
- Revenue grew 23.0% year-over-year in the last reported quarter, showcasing robust demand for its robotic surgical systems.
- Net margins remained healthy at 28.15%, reflecting the company's pricing power and efficient cost structure in the medical device sector.
- Major institutional investors like Brighton Jones LLC and Meeder Asset Management Inc. have significantly increased their stakes, signaling confidence in the long-term outlook.
- Analysts project $9 EPS for the current fiscal year and $10 for the next, suggesting sustained growth expectations from Wall Street.
Risk Factors
- Director Amy Ladd sold 119 shares in April, reducing her position by nearly 50%, which could indicate a lack of immediate confidence or portfolio rebalancing.
- EVP Gary Loeb sold 400 shares in June, decreasing his ownership by 6.54%, adding to the narrative of insider selling activity.
- Insiders have collectively sold over $3 million worth of stock in the last three months, totaling 7,169 shares, which may warrant attention from value investors.
Intuitive Surgical has introduced the EndoWrist Stapler 45, a single-patient-use robotic stapling instrument designed for its da Vinci Xi and X systems. This new accessory enables wristed articulation and integrated software confirmation for clamp and firing conditions, specifically targeting complex colorectal and thoracic procedures such as low anterior resections and sigmoid colectomies.
The device is intended to extend the dexterity of Intuitive's robotic platform by allowing surgeons to perform stapling and transection tasks entirely within the robotic system, eliminating the need to switch to handheld laparoscopic devices. Clinical observations suggest this integration improves workflow and control in deep pelvic cases, though total operating room time remains higher than conventional laparoscopy.
Financially, the EndoWrist Stapler 45 contributes to Intuitive Surgical's recurring revenue model, which analysts note now accounts for over 70% of total sales. The instrument is reimbursed as part of the overall procedure cost in the US, with per-case pricing negotiated through multi-year purchasing agreements that typically involve multiple reloads per surgery.
Intuitive segments these instruments under 'Instruments and Accessories' in SEC filings, a category that grew double digits year-over-year in 2025. With over 9,000 da Vinci systems installed worldwide, the recurring revenue from accessories like this stapler remains a key metric for investors tracking the company's financial performance and growth trajectory.
🔧 Intuitive Surgical launches da Vinci-compatible EndoWrist Stapler 45.
📈 Single-use accessories now drive over 70% of total sales.
📊 Instruments segment grew double digits in 2025 on high volume.
🏥 US reimbursement covers stapler cost within overall procedure fees.
🔬 Studies show reduced open surgery conversion rates for pelvic cases.
🔧 Intuitive Surgical launches the EndoWrist Stapler 45, a single-patient-use robotic stapling instrument compatible with da Vinci Xi and X systems.
📈 The new accessory supports complex colorectal and thoracic procedures by enabling wristed articulation and integrated software checks for clamp and firing conditions.
💰 Recurring revenue from single-use accessories like this stapler now constitutes more than 70% of Intuitive Surgical's total sales.
📊 The 'Instruments and Accessories' segment grew double digits year-over-year in 2025, driven by high procedure volumes on the installed da Vinci base.
🏥 In the US market, the stapler is reimbursed as part of the overall procedure cost rather than billed separately to patients.
🔬 Clinical studies indicate robotic stapling can reduce conversion rates to open surgery in difficult pelvic cases compared to conventional methods.
⚙️ The device uses 45 mm reload cartridges with color-coding and software checks to reduce risks of misfires or improper tissue compression.
👨⚕️ Surgeons utilize the instrument for tasks like dividing bowel and mesentery, maintaining full robotic control without switching to handheld devices.
💵 Per-case instrument costs are negotiated in multi-year agreements, typically ranging from mid-three-digit to low-four-digit dollars when combining staplers and reloads.
Bullish Signals
- EndoWrist Stapler 45 extends da Vinci dexterity for stapling.
- Recurring accessory revenue exceeds 70% of total sales.
- Instruments segment achieved double-digit year-over-year growth in 2025.
- Robotic stapling reduces conversion to open surgery in pelvic cases.
Risk Factors
- Robotic procedure costs exceed conventional laparoscopy.
- Instrument reimbursement bundled limits standalone pricing.
Bullish Signals
- The EndoWrist Stapler 45 extends the da Vinci system's dexterity to stapling tasks that previously required laparoscopic devices, enhancing clinical workflow.
- Recurring revenue from single-use accessories now makes up over 70% of Intuitive Surgical's total sales, providing a stable financial foundation.
- The 'Instruments and Accessories' segment achieved double-digit year-over-year growth in 2025, highlighting the strength of the consumables business model.
- Clinical data suggests robotic stapling reduces conversion rates to open surgery in difficult pelvic cases, potentially improving patient outcomes.
Risk Factors
- Total operating room time and cost for robotic procedures remain higher than conventional laparoscopy according to comparative datasets cited by hospital cost committees.
- The instrument is reimbursed as part of the overall procedure cost rather than billed separately, which may limit standalone pricing power.
Piper Sandler has restated its rating on Intuitive Surgical (ISRG) to Overweight with a $580 price target, citing solid fundamentals and dismissing prevailing market concerns as exaggerated. A recent field check with a prominent U.S. healthcare institution confirmed the company's positive standing, noting significant expertise in the da Vinci system, particularly the DV5 model.
The analyst firm identified several long-term growth catalysts for Intuitive Surgical, including expansion into ambulatory surgery centers, new cardiovascular treatments using the DV5 system, and the My Intuitive+ platform. Additionally, upgrades to the da Vinci 5 robotic surgical system featuring improved telepresence and longer tool use are expected to be ready in June, pending regulatory clearance.
Despite acknowledging investment risks, Piper Sandler maintains conviction in ISRG's business model. However, the article concludes with a promotional pitch suggesting that certain AI stocks offer higher returns over shorter timeframes than Intuitive Surgical, directing readers to other reports for potential high-upside opportunities.
📈 Piper Sandler rates Intuitive Surgical Overweight with $580 target.
🏥 Major U.S. hospital confirms strong da Vinci system expertise.
🚀 Growth driven by ASC expansion, new treatments, and My Intuitive+.
⚙️ da Vinci 5 upgrades expected in June pending regulatory clearance.
💬 Piper Sandler says fundamental concerns are exaggerated.
📈 Piper Sandler restated its rating on Intuitive Surgical (ISRG) to Overweight with a $580 price target.
🏥 A field check with a major U.S. healthcare institution confirmed strong expertise in the da Vinci system and DV5 model.
🚀 Key growth catalysts include ambulatory surgery center expansion, new cardiovascular treatments, and the My Intuitive+ platform.
⚙️ Upgrades to the da Vinci 5 system, including improved telepresence and longer tool use, are expected in June subject to regulatory clearance.
💬 Piper Sandler asserts that prevailing concerns about the company's fundamentals are blown out of proportion.
📉 The article includes a promotional pitch suggesting other AI stocks may offer higher returns than ISRG.
Bullish Signals
- Piper Sandler upgraded rating to Overweight with $580 target.
- Healthcare field check confirmed significant expertise in da Vinci system.
- Expansion into ambulatory centers and new cardiovascular treatments via DV5.
- da Vinci 5 upgrades expected to launch in June.
Risk Factors
- General investment risks acknowledged but unspecified as material.
- Da Vinci 5 upgrades face regulatory clearance delays.
Bullish Signals
- Piper Sandler has upgraded its rating to Overweight and set a $580 price target, indicating strong institutional confidence in the company's long-term viability.
- A field check with a prominent healthcare institution confirmed significant expertise in Intuitive Surgical's da Vinci system, validating market adoption.
- The company is pursuing multiple growth catalysts including expansion into ambulatory surgery centers and new cardiovascular treatments via the DV5 model.
- Upgrades to the da Vinci 5 robotic surgical system are expected to launch in June, potentially enhancing product capabilities and competitive positioning.
Risk Factors
- The article notes that Piper Sandler acknowledges general investment risks associated with ISRG, though it does not specify them as material threats.
- Upgrades to the da Vinci 5 system are explicitly stated to be subject to regulatory clearance, introducing a potential delay or approval risk.
Intuitive Surgical (ISRG) reported standout Q1 2023 results, beating analyst estimates with revenue of $1.70 billion, a 14% year-over-year increase, and adjusted earnings of $1.23 per share versus the expected $1.20. The surge was driven by a 26% jump in procedure volumes as hospitals cleared post-pandemic backlogs. Consequently, management raised its full-year procedure growth forecast to 18–21%, up from the previous 12–16% range, signaling robust demand ahead.
The company maintains an exceptionally strong balance sheet with virtually no debt and a cash reserve of $6.58 billion as of Q1 2023. Intuitive has never paid a cash dividend, instead returning capital through significant share repurchases, including $350 million in the first quarter alone. This conservative capital structure provides ample flexibility for R&D, acquisitions, and shareholder returns without financial strain.
Despite its strengths, ISRG faces risks including competition from major medical device firms like Medtronic and Johnson & Johnson developing their own robotic platforms. The stock trades at a premium valuation of approximately 70x trailing earnings, reflecting high growth expectations but also exposing it to potential volatility if growth slows or legal challenges regarding antitrust practices materialize.
Analysts note that flatlining growth in new system placements and a shift toward leasing arrangements could signal market saturation or increased cost sensitivity among customers. Additionally, the sustainability of procedure growth after backlog normalization and the timing of the next-generation robotic system launch remain key uncertainties for investors monitoring the company's future trajectory.
📈 Q1 2023 revenue hit $1.70B, up 14% YoY.
💰 Adjusted EPS reached $1.23, beating the $1.20 forecast.
🚀 Procedure volumes surged 26%, raising full-year growth guidance to 18–21%.
📈 Shares rallied ~9% to $294 after earnings beat.
🛡️ Company remains debt-free with $6.58B in cash and investments.
📈 ISRG reported Q1 2023 revenue of $1.70 billion, up 14% YoY, beating consensus estimates of $1.60 billion.
💰 Adjusted earnings reached $1.23 per share, surpassing the forecast of approximately $1.20 per share.
🚀 Procedure volumes surged 26% as hospitals worked through surgical backlogs, driving core business growth.
📈 Management raised the full-year procedure growth forecast to 18–21%, up from the prior 12–16% guidance.
📉 Shares rallied approximately 9–10% to trade near $294 following the earnings beat and positive outlook.
💵 The company repurchased $350 million of shares in Q1 2023, continuing a trend of major buybacks totaling $2.6 billion in 2022.
🛡️ Intuitive Surgical maintains a debt-free balance sheet with $6.58 billion in cash and investments as of Q1 2023.
⚖️ The stock trades at a premium valuation of roughly 70x trailing earnings, significantly higher than peers like Medtronic.
🤖 Competitors such as Medtronic are advancing their own robotic platforms, posing potential long-term competitive threats.
⚠️ New system placements were flat in Q1 2023 compared to the prior year, suggesting potential market saturation.
📉 GAAP net income declined slightly quarter-over-quarter despite higher revenues, indicating margin pressure.
⚖️ The company faces ongoing antitrust litigation and product liability lawsuits that could impact future operations.
🌍 International exposure to markets like China introduces regulatory and trade policy risks for growth.
🔮 A next-generation multi-port robotic system is expected to launch in 2024 or beyond, pending development progress.
📉 A shift toward leasing arrangements for new systems may defer revenue recognition and compress near-term margins.
Bullish Signals
- Revenue up 14% to $1.70 billion, beating estimates.
- Adjusted EPS of $1.23 topped forecasts.
- Procedure volumes surged 26% showing strong demand.
- Guidance raised to 18–21% procedure growth.
- Stock jumped 9–10% post-earnings.
- $6.58 billion cash with zero long-term debt.
- $350 million share repurchases in Q1 2023.
- $1.49 billion operating cash flow covers needs.
Risk Factors
- Stock trades at 70x earnings premium.
- Q1 2023 system placements were flat.
- Medtronic competitors threaten market dominance.
- China exposure adds regulatory risk.
Bullish Signals
- Revenue of $1.70 billion represented a 14% year-over-year increase, significantly exceeding analyst consensus estimates.
- Adjusted earnings per share of $1.23 topped forecasts, demonstrating strong operational profitability.
- Procedure volumes surged 26%, indicating robust demand and successful backlog recovery in the core business.
- Management raised full-year procedure growth guidance to 18–21%, reflecting high confidence in future demand.
- The stock price jumped approximately 9–10% post-earnings, validating market enthusiasm for the results.
- Intuitive maintains a fortress balance sheet with $6.58 billion in cash and zero long-term debt obligations.
- Significant share repurchases of $350 million in Q1 2023 demonstrate management's commitment to returning capital.
- Strong operating cash flow of $1.49 billion for the full year 2022 comfortably covers capital needs and buybacks.
Risk Factors
- The stock trades at a premium valuation of approximately 70x trailing earnings, creating vulnerability to growth slowdowns.
- New system placements were flat in Q1 2023 compared to the prior year, signaling potential market saturation.
- Emerging competitors like Medtronic are developing robotic platforms that could erode Intuitive's market dominance.
- International exposure to markets like China introduces risks from trade policies and foreign regulations.
Intuitive Surgical (ISRG) saw significant institutional activity in the first quarter, led by Fjarde AP Fonden boosting its stake by 57.7% to a value of $59.68 million. Several other smaller investors also increased or initiated positions, while institutional ownership remains high at 83.64%. Conversely, insider selling was notable, with EVP Gary Loeb and Director Amy Ladd reducing their holdings under pre-arranged trading plans, totaling over $3 million in sales during the quarter.
Analyst sentiment for ISRG is mixed but generally positive, with a consensus price target of $573.42 based on 19 Buy ratings versus 7 Hold and 1 Sell. Recent reports include TD Cowen lowering its target to $585 while maintaining a Buy rating, Mizuho setting a neutral target at $525, and Zacks Research downgrading the stock from Strong-Buy to Hold. The average analyst price target reflects a moderate buy consensus despite some recent downgrades.
Financially, Intuitive Surgical reported strong Q1 results with revenue of $2.77 billion, beating estimates by 5.7% and growing 23% year-over-year. The company posted $2.50 EPS, significantly above the $2.08 consensus, resulting in a net margin of 28.15%. With a market cap of $150.88 billion and a P/E ratio of 51.64, the stock trades above its 200-day moving average but below its 52-week high, reflecting recent volatility.
📈 Fjarde AP Fonden increased ISRG stake by 57.7% to $59.68 million.
💰 Q1 revenue hit $2.77 billion, beating estimates with $2.50 EPS.
📉 EVP Gary Loeb sold $169,656 of shares under Rule 10b5-1 plans.
🏦 Analysts maintain Buy ratings despite price target reductions to $585-$525.
📈 Institutional ownership stands at 83.64% with a $150.88 billion market cap.
📈 Fjarde AP Fonden increased its ISRG stake by 57.7% to $59.68 million in Q1, signaling strong institutional confidence.
📉 EVP Gary Loeb sold 400 shares worth $169,656 and Director Amy Ladd sold 119 shares worth $55,156 under Rule 10b5-1 plans.
💰 Q1 revenue reached $2.77 billion, a 23% year-over-year increase that beat analyst estimates of $2.62 billion.
📊 EPS for the quarter was $2.50, surpassing the consensus estimate of $2.08 by $0.42.
🎯 The company achieved a net margin of 28.15% and a return on equity of 15.98%.
📉 Zacks Research downgraded ISRG from Strong-Buy to Hold in late March.
📈 TD Cowen lowered its price target to $585 but maintained a Buy rating as of April 22nd.
🏦 Mizuho set a neutral price target of $525 on April 13th.
📉 Insider selling totaled over $3 million in the last quarter, representing 0.60% of total stock ownership.
📈 Institutional investors own 83.64% of the company's outstanding shares.
📉 The stock trades at a P/E ratio of 51.64 with a market capitalization of $150.88 billion.
📉 ISRG stock opened at $426.01, trading below its 200-day moving average of $480.00.
📈 The consensus analyst price target is $573.42 based on a Moderate Buy rating.
🏥 Intuitive Surgical focuses on robotic-assisted surgical systems like the da Vinci platform.
📉 Wall Street Zen upgraded the stock from Hold to Buy in mid-June.
Bullish Signals
- Revenue beat estimates by $150 million.
- EPS of $2.50 exceeded consensus of $2.08.
- Pension fund stake increased 57.7%.
- Net margin expanded to 28.15%.
- Analysts maintain Buy ratings.
Risk Factors
- Zacks downgraded to Hold due to valuation concerns.
- Mizuho Neutral rating with $525 target implies limited upside.
- Executives sold over $3 million in Q1.
- High P/E of 51.64 limits upside if growth slows.
- Stock trades below 200-day moving average of $480.
Bullish Signals
- Revenue of $2.77 billion beat analyst estimates by $150 million, demonstrating strong demand for robotic surgical systems.
- EPS of $2.50 significantly exceeded the consensus estimate of $2.08, indicating robust operational performance.
- Fjarde AP Fonden, a major Swedish pension fund, increased its stake by 57.7%, validating long-term investment thesis.
- Net margin expanded to 28.15% and return on equity reached 15.98%, reflecting high profitability.
- TD Cowen maintains a Buy rating despite lowering the price target, suggesting continued confidence in the business model.
- Wall Street Zen upgraded the stock from Hold to Buy in June, adding to the bullish analyst consensus.
Risk Factors
- Zacks Research downgraded the stock from Strong-Buy to Hold, citing potential valuation concerns or slowing growth.
- Mizuho assigned a Neutral rating with a $525 price target, which is below the current trading price of ~$426 but implies limited upside.
- Significant insider selling occurred in Q1, with executives and directors reducing holdings by over $3 million combined.
- The stock trades at a high P/E ratio of 51.64, which may limit upside if growth rates decelerate.
- Recent price action shows the stock trading below its 200-day moving average of $480, indicating short-term weakness.
Intuitive Surgical (NASDAQ:ISRG) saw a mixed institutional landscape in the first quarter, highlighted by ABN AMRO Bank N.V. reducing its stake by 37.1% to 40,572 shares, worth approximately $18.9 million. Conversely, several smaller hedge funds including Riversedge Advisors LLC and Fiduciary Financial Group LLC increased their positions slightly during the fourth quarter, while WoodTrust Financial Corp also added to its holdings.
Analyst sentiment remains cautiously positive despite recent downgrades from major firms like Zacks Research and UBS Group, which lowered price targets. The consensus rating is a 'Moderate Buy' with a target price of $573.42, though the stock recently traded below its 50-day moving average. Insider selling activity was notable in April and June, with directors and senior executives executing pre-arranged Rule 10b5-1 trades to reduce their personal holdings.
Financially, Intuitive Surgical delivered strong performance in the quarter ending April 21st, reporting revenue of $2.77 billion, a 23% year-over-year increase that beat analyst expectations. The company posted earnings per share of $2.50 against a consensus of $2.08, resulting in a net margin of 28.15%. With a market capitalization of $143.33 billion and a P/E ratio of 49.05, the medical robotics leader continues to demonstrate robust growth driven by its da Vinci surgical systems.
📉 ABN AMRO sold shares, reducing stake by 37.1% to $18.89 million value.
📈 Q1 revenue hit $2.77 billion, beating estimates with EPS of $2.50.
📉 Analysts lowered targets to $558 and $550 despite 'Moderate Buy' rating.
🏦 Insider selling occurred in April and June via Rule 10b5-1 plans.
📉 Stock trades at $404.70, below 50-day and 200-day moving averages.
📉 ABN AMRO Bank N.V. decreased its ISRG position by 37.1% in Q1, selling 23,961 shares while retaining a stake valued at $18.89 million.
📈 Several smaller hedge funds including Riversedge Advisors LLC and WoodTrust Financial Corp increased their stakes in the fourth quarter.
📊 Intuitive Surgical reported Q1 revenue of $2.77 billion, representing a 23% year-over-year increase compared to analyst expectations of $2.62 billion.
💰 The company posted earnings per share of $2.50, significantly topping the consensus estimate of $2.08 with a net margin of 28.15%.
📉 Analyst sentiment is mixed with recent downgrades from Zacks Research and UBS Group lowering price targets to $558 and $550 respectively.
🏦 The stock maintains a consensus 'Moderate Buy' rating with an average target price of $573.42 based on 19 buy, 7 hold, and 1 sell ratings.
📉 Insider selling activity was significant in April and June, with directors and SVPs reducing holdings via pre-arranged Rule 10b5-1 trading plans.
📈 The company has a market capitalization of $143.33 billion and trades at a P/E ratio of 49.05.
🔬 Intuitive Surgical is best known for its da Vinci surgical systems which enable minimally invasive procedures in hospitals and surgical centers.
📉 The stock opened at $404.70, trading below its 50-day moving average of $432.67 and 200-day moving average of $484.61.
Bullish Signals
- Q1 revenue hit $2.77 billion, up 23% year-over-year.
- Earnings per share reached $2.50, beating estimates by $0.42.
- Net margin of 28.15% and ROE of 15.98% reported.
- Analysts rate stock 'Moderate Buy' with $573.42 target.
Risk Factors
- Zacks Research downgraded Intuitive Surgical to 'hold' on March 30th.
- UBS cut price target from $570.00 to $550.00 with neutral rating.
- Bank of America lowered price target from $520.00 to $515.00.
- ABN AMRO Bank reduced position by 37.1% in first quarter.
- Insiders sold 7,169 shares worth $3.06 million last quarter.
Bullish Signals
- Intuitive Surgical reported Q1 revenue of $2.77 billion, a 23% year-over-year increase that exceeded analyst expectations of $2.62 billion.
- The company posted earnings per share of $2.50, beating the consensus estimate of $2.08 by $0.42.
- Intuitive Surgical achieved a strong net margin of 28.15% and a return on equity of 15.98% for the quarter.
- The stock maintains a consensus 'Moderate Buy' rating from nineteen equities research analysts with a target price of $573.42.
Risk Factors
- Zacks Research lowered its rating on Intuitive Surgical from 'strong-buy' to 'hold' in a report dated March 30th.
- UBS Group decreased its price target from $570.00 to $550.00 and set a 'neutral' rating in a report dated March 17th.
- Bank of America dropped its price target from $520.00 to $515.00 in a research note dated June 12th.
- Major institutional investor ABN AMRO Bank N.V. significantly reduced its position by 37.1% during the first quarter.
- Insiders sold a total of 7,169 shares valued at $3.06 million over the last quarter, indicating some internal profit-taking.
Intuitive Surgical, Inc. (ISRG) shares closed at $404.27, rising 1.14% despite a broader market decline where the S&P 500 and Nasdaq fell. However, the stock has underperformed over the past month, dropping 5.65% compared to gains in the Medical sector and losses in the wider S&P 500.
Analysts are anticipating strong upcoming earnings with a consensus EPS of $2.48, representing a 13.24% year-over-year increase, and revenue of $2.81 billion, up 15%. Full-year projections suggest earnings of $10.41 per share and revenue of $11.72 billion, both reflecting approximately 16.5% growth from the prior year.
Valuation metrics indicate a premium for ISRG relative to its peers, with a Forward P/E ratio of 38.4 compared to an industry average of 24.67 and a PEG ratio of 2.68 versus 2.23. The company currently holds a Zacks Rank #2 (Buy) rating, while the broader Medical Instruments industry ranks in the bottom 38% of all tracked industries.
📈 ISRG shares rose 1.14% to $404.27, outperforming major indices.
📉 Stock dropped 5.65% this month, lagging the Medical sector.
💰 Analysts forecast quarterly EPS of $2.48 and revenue of $2.81B.
📊 Forward P/E is 38.4x, well above the industry average of 24.67x.
🏆 Holds Zacks Rank #2 (Buy) with stable analyst estimates.
📈 ISRG shares closed up 1.14% at $404.27, outperforming the S&P 500 and Nasdaq during a market dip.
📉 The stock has declined 5.65% over the past month, trailing the Medical sector's positive performance.
💰 Analysts forecast upcoming quarterly EPS of $2.48 (13.24% growth) and revenue of $2.81 billion (15% growth).
📅 Full-year consensus estimates project earnings of $10.41 per share and revenue of $11.72 billion.
📊 The company trades at a Forward P/E of 38.4, significantly higher than the industry average of 24.67.
📉 ISRG has a PEG ratio of 2.68 compared to an industry average of 2.23.
🏆 Intuitive Surgical holds a Zacks Rank #2 (Buy) based on analyst estimate stability.
🏭 The Medical Instruments industry ranks in the bottom 38% of all 250+ industries tracked by Zacks.
Bullish Signals
- Shares rose 1.14% to $404.27, outperforming major indices.
- EPS projected at $2.48, up 13.24% YoY.
- Revenue expected at $2.81 billion, up 15% YoY.
- Full-year earnings estimated at $10.41 per share.
- Zacks Rank #2 (Buy) rating maintained.
Risk Factors
- Stock declined 5.65% while sector and S&P 500 moved differently.
- Forward P/E of 38.4 is much higher than industry average of 24.67.
- PEG ratio of 2.68 exceeds industry average of 2.23, implying high price.
Bullish Signals
- ISRG shares rose 1.14% to close at $404.27, demonstrating resilience and outperformance against major indices like the S&P 500 and Nasdaq during a market downturn.
- Upcoming earnings are expected to show robust growth with EPS projected at $2.48 (13.24% YoY) and revenue at $2.81 billion (15% YoY).
- Full-year analyst consensus indicates continued expansion with estimated earnings of $10.41 per share and revenue of $11.72 billion, both up approximately 16.5% from last year.
- The company maintains a Zacks Rank #2 (Buy) rating, suggesting analysts see stable or improving near-term business trends.
Risk Factors
- ISRG has underperformed over the past month with a 5.65% decline, falling short of the Medical sector's gain and the S&P 500's loss.
- The stock trades at a Forward P/E ratio of 38.4, which is substantially higher than the industry average of 24.67, indicating a premium valuation.
- ISRG's PEG ratio of 2.68 exceeds the industry average of 2.23, suggesting the current price may be high relative to its expected earnings growth rate.
